ONO-4059 analog

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

ONO-4059 analog  纯度: 99.76%

ONO-4059 analog 是 ONO-4059 的类似物，ONO-405是一种高效的选择性Btk抑制剂。

ONO-4059 analog

ONO-4059 analog Chemical Structure

CAS No. : 1351635-67-0

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ￥1210 In-stock
5 mg ￥1100 In-stock
10 mg ￥1800 In-stock
25 mg ￥3200 In-stock
50 mg ￥5500 In-stock
100 mg ￥7940 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

ONO-4059 analog 相关产品

•相关化合物库:

  • Covalent Screening Library Plus
  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Kinase Inhibitor Library
  • Protein Tyrosine Kinase Compound Library
  • Anti-Cancer Compound Library
  • Covalent Screening Library
  • Anti-Blood Cancer Compound Library

生物活性

ONO-4059 analog is the analog of ONO-4059, ONO-4059 is a highly potent and selective Btk inhibitor. IC50 value: sub-nM range [2] Target: Btk in vitro: ONO-4059 is a selective, once-daily, oral inhibitor of BTK, which has been shown to play a role in the survival and proliferation of malignant B-cells. ONO-4059 shows a favourable safety profile along with promising efficacy in this difficult-to-treat patient population. [1] in vivo: ONO-4059 has demonstrated anti-tumour activity in several pre-clinical models.[1] ONO-4059 potently and dose-dependently reverse clinical arthritis and prevented bone damage in the CIA model.[2]

分子量

456.50

Formula

C25H24N6O3
CAS 号

1351635-67-0
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : ≥ 29 mg/mL (63.53 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.1906 mL 10.9529 mL 21.9058 mL
5 mM 0.4381 mL 2.1906 mL 4.3812 mL
10 mM 0.2191 mL 1.0953 mL 2.1906 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
参考文献

  • [1]. Simon Rule,A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory B-Cell Lymphoma. November 15, 2013; Blood: 122 (21)

    [2]. Toshio Yoshizawa, et al. Development of a Bruton’s Tyrosine Kinase (Btk) Inhibitor, ONO-4059: Efficacy in a Collagen Induced Arthritis (CIA) Model Indicates Potential Treatment for Rheumatoid Arthritis (RA). Washington, DC November 9-14, 2012.

    [3]. Yamamoto, et al. Preparation of purinone derivatives as selective Btk inhibitors. From PCT Int. Appl. (2011), WO 2011152351 A1 20111208.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务